One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
Celerion, Tempe, Arizona, United States
ICON Phase I Clinic, Salt Lake City, Utah, United States
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Overland Park, Kansas, Overland Park, Kansas, United States
The First Affiliated Hospital of Guangzhou University of Chinese medicine, Guangzhou, China
Local Institution - 0001, Québec, CA, Canada
CMH Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan
ICON Early Development Services, Salt Lake City, Utah, United States
Hammersmith Medicines Research, London, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.